BOLT RSI Chart
Last 7 days
-36.5%
Last 30 days
-27.9%
Last 90 days
-33.3%
Trailing 12 Months
-57.9%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 11.3M | 0 | 0 | 0 |
2023 | 6.7M | 6.8M | 7.2M | 7.9M |
2022 | 2.2M | 3.5M | 4.8M | 5.7M |
2021 | 0 | 269.0K | 970.0K | 1.4M |
2020 | 0 | 0 | 0 | 257.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Dec 12, 2023 | quinn william p. | bought | 7,125 | 0.95 | 7,500 | chief financial officer |
Dec 06, 2023 | quinn william p. | bought | 1,955 | 0.782 | 2,500 | chief financial officer |
Dec 06, 2023 | perez edith a. | bought | 1,955 | 0.782 | 2,500 | chief medical officer |
Dec 06, 2023 | yonehiro grant | bought | 1,955 | 0.782 | 2,500 | chief business officer |
Dec 06, 2023 | schatzman randall c | bought | 1,955 | 0.782 | 2,500 | chief executive officer |
Nov 30, 2023 | engleman edgar | sold | -92,799 | 0.8581 | -108,145 | - |
Nov 30, 2023 | engleman edgar | sold | -12,814 | 0.8581 | -14,934 | - |
Nov 29, 2023 | engleman edgar | sold | -20,542 | 0.906 | -22,674 | - |
Nov 29, 2023 | engleman edgar | sold | -2,836 | 0.906 | -3,131 | - |
Nov 21, 2023 | vivo capital viii, llc | sold | -1,536 | 0.9 | -1,707 | - |
Which funds bought or sold BOLT recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | JANE STREET GROUP, LLC | sold off | -100 | -63,016 | - | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | reduced | -32.66 | -1,460 | 7,764 | -% |
May 15, 2024 | CITADEL ADVISORS LLC | reduced | -1.76 | 627,986 | 3,382,020 | -% |
May 15, 2024 | Royal Bank of Canada | reduced | -99.78 | - | - | -% |
May 15, 2024 | ORBIMED ADVISORS LLC | unchanged | - | 431,480 | 2,157,400 | 0.04% |
May 15, 2024 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | unchanged | - | 31,136 | 155,680 | -% |
May 15, 2024 | ADAGE CAPITAL PARTNERS GP, L.L.C. | unchanged | - | 140,000 | 700,000 | -% |
May 15, 2024 | TANG CAPITAL MANAGEMENT LLC | reduced | -6.36 | 697,487 | 4,788,000 | 0.50% |
May 15, 2024 | MILLENNIUM MANAGEMENT LLC | reduced | -2.24 | 11,690 | 64,338 | -% |
May 15, 2024 | Board of Trustees of The Leland Stanford Junior University | unchanged | - | 201,473 | 1,007,360 | 0.09% |
Unveiling Bolt Biotherapeutics, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Bolt Biotherapeutics, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Bolt Biotherapeutics, Inc. News
Income Statement (Quarterly) | |||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 |
Revenue | 152.5% | 5,274 | 2,089 | 2,528 | 1,433 | 1,826 | 1,411 | 2,112 | 1,393 | 813 | 508 | 752 | 176 | - | 42.00 | 51.00 | 164 |
Operating Expenses | 2.3% | 22,366 | 21,855 | 20,711 | 21,265 | 20,241 | 22,451 | 24,458 | 24,452 | 24,689 | 27,583 | 24,278 | 23,761 | 16,922 | 12,405 | 11,177 | 8,909 |
S&GA Expenses | -100.0% | - | 5,533 | 5,760 | 5,621 | 5,616 | 5,606 | 5,485 | 5,532 | 6,304 | 5,099 | 4,941 | 4,054 | 2,058 | 2,865 | 2,011 | 2,122 |
R&D Expenses | 1.3% | 16,529 | 16,322 | 14,951 | 15,644 | 14,625 | 16,845 | 18,973 | 18,920 | 18,385 | 22,484 | 19,337 | 19,707 | 14,864 | 9,540 | 9,166 | 6,787 |
Net Income | 39.6% | -10,811 | -17,903 | -16,257 | -18,057 | -16,980 | -19,997 | -21,759 | -22,664 | -23,678 | -27,157 | -23,395 | -23,585 | -31,035 | -10,001 | -11,059 | -8,633 |
Net Income Margin | 36.6% | -5.57* | -8.79* | -9.90* | -11.32* | -12.07* | -15.38* | -19.74* | -27.96* | -43.49* | -68.66* | -105.64* | -331.13* | - | - | - | - |
Free Cashflow | -17.4% | -16,751 | -14,271 | -16,914 | -15,144 | -23,402 | -18,136 | -14,186 | -21,216 | -24,919 | -18,356 | -19,742 | -4,689 | - | - | - | - |
Balance Sheet | |||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 |
Assets | -10.6% | 143 | 160 | 175 | 191 | 206 | 228 | 246 | 260 | 283 | 308 | 334 | 347 | 325 | 47.00 |
Current Assets | -10.1% | 95.00 | 106 | 125 | 131 | 132 | 173 | 175 | 181 | 196 | 189 | 222 | 248 | 271 | 25.00 |
Cash Equivalents | -60.6% | 4.00 | 11.00 | 9.00 | 13.00 | 15.00 | 9.00 | 11.00 | 23.00 | 44.00 | 27.00 | 24.00 | 58.00 | 95.00 | 6.00 |
Net PPE | -9.2% | 4.00 | 5.00 | 5.00 | 6.00 | 6.00 | 6.00 | 7.00 | 7.00 | 7.00 | 6.00 | 6.00 | 5.00 | 4.00 | 4.00 |
Liabilities | -17.7% | 39.00 | 47.00 | 47.00 | 49.00 | 48.00 | 56.00 | 57.00 | 52.00 | 54.00 | 58.00 | 59.00 | 51.00 | 21.00 | 46.00 |
Current Liabilities | -18.2% | 17.00 | 20.00 | 19.00 | 18.00 | 16.00 | 23.00 | 24.00 | 19.00 | 19.00 | 21.00 | 24.00 | 19.00 | 12.00 | 11.00 |
Shareholder's Equity | -7.6% | 104 | 113 | 128 | 142 | 158 | 172 | 188 | 208 | 228 | 250 | 275 | 296 | 303 | - |
Retained Earnings | -3.0% | -375 | -364 | -346 | -330 | -312 | -295 | -275 | -253 | -230 | -206 | -179 | -156 | -132 | -108 |
Additional Paid-In Capital | 0.5% | 479 | 477 | 475 | 472 | 470 | 468 | 465 | 463 | 460 | 457 | 455 | 452 | 436 | 3.00 |
Shares Outstanding | 0.0% | 38.00 | 38.00 | 38.00 | 38.00 | 38.00 | 38.00 | 37.00 | 37.00 | 37.00 | 37.00 | 32.00 | 29.00 | 21.00 | - |
Float | - | - | - | - | 32.00 | - | - | - | 51.00 | - | - | - | 383 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 |
Cashflow From Operations | -17.4% | -16,751 | -14,265 | -16,749 | -15,112 | -23,399 | -17,952 | -13,451 | -20,787 | -24,314 | -17,794 | -18,727 | -3,986 | -16,559 | -12,890 | -12,515 | -12,265 | -9,638 |
Share Based Compensation | -47.3% | 2,302 | 4,372 | 33.00 | 39.00 | 2,476 | 4,290 | 100 | 100 | 2,919 | 4,167 | 100 | 100 | 2,109 | 569 | 403 | 223 | 225 |
Cashflow From Investing | -35.5% | 10,203 | 15,809 | 12,658 | 13,580 | 28,991 | 16,435 | 1,450 | -868 | 40,845 | 21,033 | -16,111 | -46,602 | -190,521 | 1,704 | -13,095 | 4,407 | -13,608 |
Cashflow From Financing | -100.0% | - | 106 | - | - | - | 144 | - | 252 | 107 | 495 | 185 | 13,409 | 297,019 | -1,065 | -923 | 41,551 | 34.00 |
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||
Collaboration revenue | $ 5,274 | $ 1,826 |
Operating expenses: | ||
Research and development | 16,529 | 14,625 |
General and administrative | 5,837 | 5,616 |
Total operating expense | 22,366 | 20,241 |
Loss from operations | (17,092) | (18,415) |
Other income, net | ||
Interest income, net | 1,606 | 1,435 |
Other income | 4,675 | |
Total other income, net | 6,281 | 1,435 |
Net loss | (10,811) | (16,980) |
Net unrealized (loss) gain on marketable securities | (73) | 684 |
Comprehensive loss | $ (10,884) | $ (16,296) |
Net loss per share, basic | $ (0.28) | $ (0.45) |
Net loss per share, diluted | $ (0.28) | $ (0.45) |
Weighted-average shares outstanding, basic | 38,068,424 | 37,684,023 |
Weighted-average shares outstanding, diluted | 38,068,424 | 37,684,023 |
CONDENSED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 4,262 | $ 10,810 |
Short-term investments | 87,088 | 91,379 |
Prepaid expenses and other current assets | 3,705 | 3,519 |
Total current assets | 95,055 | 105,708 |
Property and equipment, net | 4,499 | 4,957 |
Operating lease right-of-use assets | 18,347 | 19,120 |
Restricted cash | 1,765 | 1,765 |
Long-term investments | 21,461 | 26,413 |
Other assets | 1,765 | 1,821 |
Total assets | 142,892 | 159,784 |
Current liabilities: | ||
Accounts payable | 2,219 | 2,987 |
Accrued expenses and other current liabilities | 9,710 | 12,486 |
Deferred revenue | 1,907 | 2,201 |
Operating lease liabilities | 2,887 | 2,782 |
Total current liabilities | 16,723 | 20,456 |
Operating lease liabilities, net of current portion | 16,680 | 17,437 |
Deferred revenue, non-current | 5,330 | 9,107 |
Other long-term liabilities | 0 | 43 |
Total liabilities | 38,733 | 47,043 |
Commitments and contingencies (Note 7) | ||
Stockholders' equity (deficit): | ||
Preferred stock, $0.00001 par value, authorized shares-10,000,000 shares authorized at March 31, 2024 and December 31, 2023; zero shares issued and outstanding at March 31, 2024 and December 31, 2023 | 0 | 0 |
Common stock, $0.00001 par value; 200,000,000 shares authorized at March 31, 2024 and December 31, 2023; 38,127,740 and 38,114,606 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 1 | 1 |
Additional paid-in capital | 479,290 | 476,988 |
Accumulated other comprehensive (loss) gain | (36) | 37 |
Accumulated deficit | (375,096) | (364,285) |
Total stockholders' equity: | 104,159 | 112,741 |
Total liabilities and stockholders' equity | $ 142,892 | $ 159,784 |